drugset / Trial / NCT00631449

Raltegravir Intensification in HIV-infected Patients

NCT00631449

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.

Timeline

Start
2008-02
Primary completion
2009-09
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Raltegravir Other / unclassified 400 mg Oral